Marked by their passionate support of Taylor Swift, several rheumatologists, rheumatology professionals and ACR staff who identify as Swifties spoke to us about their in-depth knowledge of Swift’s music and active engagement in fan discussions and events.
Rheumatology workforce challenges are a global concern. Many challenges, especially the lack of trained rheumatology clinicians, are similar among countries and regions of the world, while others differ. The 2024 ACR Global Summit session on workforce featured a discussion by representatives of regional rheumatology organizations and the ACR addressing issues central to developing and retaining…
For the 2024 Image Competition, the ACR sought images with educational or remarkable manifestations representing a diverse range of pediatric patients with autoimmune, inflammatory, infectious and malignant drivers of rheumatic disease. Here, we showcase the winning images from the Middle East and North Africa. Lipoma Arborescens Revealed A 10-year-old boy, presented with a five-year history…
‘Cannabis has a long history of being used for pain management,’ says Physician Editor Bharat Kumar, MD, MME, FACP, FAAAAI, RhMSUS. ‘What does it mean for rheumatology patients moving forward? Read our article for one answer to this question.’ As cannabis becomes more widely legalized, both in the U.S. and internationally, its use for pain…
This annual event, to be held May 4–6, brings together the rheumatology community to advocate on Capitol Hill for the profession and rheumatic disease patients.
Medicare’s current telehealth flexibilities are set to expire March 31. To avoid a government shutdown, Congress must pass a appropriations package by midnight on March 14. The ACR is preparing for the impacts if a telehealth extension does not pass.
Inebilizumab reduces the risk of immunoglobulin G4-related disease (IgG4-RD) flares and increases the likelihood of flare-free, complete remission at one year, a recent study shows.1 The randomized, doubleblind, placebo-controlled MITIGATE trial showed that inebilizumab reduced the risk of IgG4-RD symptoms by 87%, compared with placebo. About IgG4-RD IgG4-RD is chronic, rare condition that has, so…
The transition from being a rheumatology fellow to being in private practice is significant. As I reflect on the past two years, I want to share my observations and begin a conversation about how to prepare rheumatology fellows for careers as practicing rheumatologists. The difference between learning about rheumatology and practicing rheumatology is nuanced. Upon…
Over 50% of patients with systemic sclerosis (SSc) develop interstitial lung disease (ILD), and rheumatologists have long recognized this major cause of morbidity and mortality.1 Sindhu R. Johnson, MD, PhD, professor of medicine at the University of Toronto, Canada, and director of the Toronto Scleroderma Program, notes that more recent studies have increased our awareness…
My children were playing in the car the other day and pulled open the glove box. Inside, they found a brown paper bag with my last name “KUMAR” in black Sharpie and a red sticker that read, “Do not lose. No replacements available.” It wasn’t long before the kids tore that bag apart to find…